• Most Popular
  • Most Shared

Keryx licenses rights to Japan Tobacco for drug development

Wed Sep 26, 2007 7:47am EDT

Stocks

   

Sept 26 (Reuters) - Keryx Biopharmaceuticals Inc (KERX.O) said it entered into a licensing pact with Japan Tobacco Inc (2914.T) and its unit to give them the exclusive rights to develop and market its drug candidate Zerenex in Japan.

Under the agreement, Japan Tobacco and its unit, Torii Pharmaceutical Co Ltd (4551.T) will pay up to $100 million in up-front license fees and payments. Zerenex, which is for the treatment of elevated phosphate levels in patients with end-stage renal disease, is currently in mid-stage trials in the United States. (Reporting by Esha Dey in Bangalore)



More from Reuters

Photo

Exclusive: U.S. business investment showing life

CHICAGO (Reuters) - A trade group for the lenders that finance half the capital equipment investment in the United States said on Tuesday the sharp pullback in business borrowing that marked the recent downturn moderated markedly in November -- an encouraging sign companies may be growing more confident in the sustainability of the recovery.

» More Top News
Malaysians participate in computer attack and defence hacking competition during The 3rd Annual Hack-In-The-Box Security Conference 2004 in Kuala Lumpur on October 6, 2004. REUTERS/Bazuki Muhammad
Commentary:

Year of the breach

Data security breaches are nasty business and should be avoided at all costs, writes Kevin Prince, a chief technology officer at Perimeter e-Security. Here's a look at the biggest breaches and blunders of 2009.  Commentary 

Technology
Soldiers look on as U.S. Secretary of Defense Robert Gates speaks to soldiers at F.O.B. Warrior in Kirkuk, Iraq December 11, 2009. REUTERS/Justin Sullivan/Pool

Are you pregnant? Sir! No, Sir!

There are some 115,000 U.S. troops in Iraq -- and one commander wants to make sure his soldiers don't multiply.  Full Article 

Politics